[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertisement
Advertise Here
August 15, 2011
Volume 89, Number 33
p. 9

Pfizer Augments Academic Network

Collaboration: San Diego hosts the drugmaker’s latest partnership

Lisa Jarvis

  • Print this article
  • Email the editor

Latest News



October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Pfizer has added another node to a growing network of academic collaborators intended to speed its discovery of protein-based drugs. The newest member of Pfizer’s Centers for Therapeutic Innovation (CTI)—the University of California, San Diego, Health Sciences—will receive up to $50 million in a five-year collaboration.

The drugmaker launched CTI in November 2010 with UC San Francisco as its first partner. Pfizer has since announced CTIs in New York City and Boston. At each location, the company is setting up labs where its scientists can directly collaborate with university partners. Each lab will house a staff of antibody engineers, assay biologists, protein scientists, and project managers, Pfizer says.

Under the CTI model, academic scientists submit proposals to a steering committee composed of university and Pfizer representatives. For every project that receives funding through CTI, Pfizer will pay for two postdoctoral or clinical fellows.

For the UCSD project, Pfizer plans to hire about 15 scientists to work with university researchers in dedicated lab space at the company’s site in La Jolla, Calif. The firm is already recruiting 30 scientists to work at its planned research center in San Francisco’s Mission Bay. Overall, the California collaborations could receive up to $150 million in research support and milestone payments if molecules they discover complete Phase I studies.

Pfizer is one of several major drug firms attempting to leverage academic expertise to lower R&D costs and improve productivity.

Kenneth I. Kaiten, director of the Tufts Center for the Study of Drug Development, says Pfizer’s partnering strategy is “particularly good” because it calls for industry and academic scientists to work side by side. “That’s something that a lot of the other plans in major companies exploring partnerships are not really allowing for,” Kaiten observes. In the process, he says, Pfizer gains access to cutting-edge science, and academics can tap into the company’s development and commercialization expertise.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!